Pancreatic Adenocarcinoma, Version 2.2012: Featured Updates to the NCCN Guidelines

Margaret A Tempero; J. Pablo Arnoletti; Stephen W Behrman; Edgar Ben-Josef; Al B Benson; Ephraim S Casper; Steven J Cohen; Brian Czito; Joshua D. I Ellenhorn; William G Hawkins; Joseph Herman; John P Hoffman; Andrew Ko; Srinadh Komanduri; Albert Koong; Wen Wee Ma; Mokenge P Malafa; Nipun B Merchant; Sean J Mulvihill; Peter Muscarella; Eric K Nakakura; Jorge Obando; Martha B Pitman; Aaron R Sasson; Anitra Tally; Sarah P Thayer; Samuel Whiting; Robert A Wolff; Brian M Wolpin; Deborah A Freedman-Cass; Dorothy A Shead; National Comprehensive Cancer Networks

doi:10.6004/jnccn.2012.0073

Back

Pancreatic Adenocarcinoma, Version 2.2012: Featured Updates to the NCCN Guidelines

Journal article

Open access

Pancreatic Adenocarcinoma, Version 2.2012: Featured Updates to the NCCN Guidelines

Margaret A Tempero, J. Pablo Arnoletti, Stephen W Behrman, Edgar Ben-Josef, Al B Benson, Ephraim S Casper, Steven J Cohen, Brian Czito, Joshua D. I Ellenhorn, William G Hawkins, …

Journal of the National Comprehensive Cancer Network, Vol.10(6), pp.703-713

2012-06-01

DOI: https://doi.org/10.6004/jnccn.2012.0073

PMCID: PMC3807091

PMID: 22679115

Abstract

The NCCN Clinical Practice Guidelines in Oncology (NCCN Guidelines) for Pancreatic Adenocarcinoma discuss the workup and management of tumors of the exocrine pancreas. These NCCN Guidelines Insights provide a summary and explanation of major changes to the 2012 NCCN Guidelines for Pancreatic Adenocarcinoma. The panel made 3 significant updates to the guidelines: 1) more detail was added regarding multiphase CT techniques for diagnosis and staging of pancreatic cancer, and pancreas protocol MRI was added as an emerging alternative to CT; 2) the use of a fluoropyrimidine plus oxaliplatin (e.g., 5-FU/leucovorin/oxaliplatin or capecitabine/oxaliplatin) was added as an acceptable chemotherapy combination for patients with advanced or metastatic disease and good performance status as a category 2B recommendation; and 3) the panel developed new recommendations concerning surgical technique and pathologic analysis and reporting.

Files and links (1)

url

https://doi.org/10.6004/jnccn.2012.0073View

Published (Version of record) Open

Metrics

7 Record Views

226 Times Cited - Web of Science

See more details

InCites Highlights

These are selected metrics from InCites Benchmarking & Analytics tool, related to this output

Collaboration types: Domestic collaboration
Citation topics: 1 Clinical & Life Sciences; 1.151 Pancreas & Gall Bladder Disorders; 1.151.395 Pancreatic Cancer
Web Of Science research areas: Oncology
ESI research areas: Clinical Medicine

UN Sustainable Development Goals (SDGs)

This output has contributed to the advancement of the following goals:

Source: InCites

Details

Title: Pancreatic Adenocarcinoma, Version 2.2012
Creators: Margaret A Tempero - UCSF Helen Diller Family Comprehensive Cancer Center
J. Pablo Arnoletti - University of Alabama at Birmingham Comprehensive Cancer Center
Stephen W Behrman - St. Jude Children's Research Hospital/University of Tennessee Cancer Institute
Edgar Ben-Josef - University of Michigan Comprehensive Cancer Center
Al B Benson - Robert H. Lurie Comprehensive Cancer Center of Northwestern University
Ephraim S Casper - Memorial Sloan-Kettering Cancer Center
Steven J Cohen - Fox Chase Cancer Center
Brian Czito - Duke Cancer Institute
Joshua D. I Ellenhorn - City of Hope Comprehensive Cancer Center
William G Hawkins - Siteman Cancer Center at Barnes-Jewish Hospital and Washington University School of Medicine
Joseph Herman - The Sidney Kimmel Comprehensive Cancer Center at Johns Hopkins
John P Hoffman - Fox Chase Cancer Center
Andrew Ko - UCSF Helen Diller Family Comprehensive Cancer Center
Srinadh Komanduri - Robert H. Lurie Comprehensive Cancer Center of Northwestern University
Albert Koong - Stanford Cancer Institute
Wen Wee Ma - Roswell Park Cancer Institute
Mokenge P Malafa - H. Lee Moffitt Cancer Center & Research Institute
Nipun B Merchant - Vanderbilt-Ingram Cancer Center
Sean J Mulvihill - Huntsman Cancer Institute at the University of Utah
Peter Muscarella - The Ohio State University Comprehensive Cancer Center - James Cancer Hospital & Solove Research Institute
Eric K Nakakura - UCSF Helen Diller Family Comprehensive Cancer Center
Jorge Obando - Duke Cancer Institute
Martha B Pitman - Massachusetts General Hospital Cancer Center
Aaron R Sasson - UNMC Eppley Cancer Center at The Nebraska Medical Center
Anitra Tally - Pancreatic Cancer Action Network (PanCAN)
Sarah P Thayer - Massachusetts General Hospital Cancer Center
Samuel Whiting - Fred Hutchinson Cancer Research Center/Seattle Cancer Care Alliance
Robert A Wolff - The University of Texas MD Anderson Cancer Center
Brian M Wolpin - Dana-Farber/Brigham and Women's Cancer Center
Deborah A Freedman-Cass - National Comprehensive Cancer Network
Dorothy A Shead - National Comprehensive Cancer Network
National Comprehensive Cancer Networks
Publication Details: Journal of the National Comprehensive Cancer Network, Vol.10(6), pp.703-713
Grant note: P01 CA117969 || CA / National Cancer Institute : NCI P50 CA127003 || CA / National Cancer Institute : NCI
Academic Unit: Miller School of Medicine; UMMG Department of Surgery; UMMG Dept of Surgery - Div of Surgical Oncology
Language: English
Resource Type: Journal article
PMID: 22679115
PMCID: PMC3807091
Record Identifier: 991031600304702976